Fortress Biotech Inc Pref Series A (FBIOP)vsModerna Inc (MRNA)
FBIOP
Fortress Biotech Inc Pref Series A
$15.87
-0.87%
HEALTHCARE · Cap: $77.81M
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 3154% more annual revenue ($2.23B vs $68.47M). FBIOP leads profitability with a 163.3% profit margin vs -141.4%. FBIOP earns a higher WallStSmart Score of 44/100 (D).
FBIOP
Hold44
out of 100
Grade: D
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$13.01
Current Price
$15.87
$2.86 discount
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 79 in profit
Keeps 163 of every $100 in revenue as profit
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : FBIOP
The strongest argument for FBIOP centers on Return on Equity, Profit Margin. Profitability is solid with margins at 163.3% and operating margin at -53.5%. Revenue growth of 14.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : FBIOP
The primary concerns for FBIOP are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
FBIOP profiles as a mature stock while MRNA is a turnaround play — different risk/reward profiles.
FBIOP carries more volatility with a beta of 1.25 — expect wider price swings.
FBIOP is growing revenue faster at 14.0% — sustainability is the question.
FBIOP generates stronger free cash flow (-59M), providing more financial flexibility.
Bottom Line
FBIOP scores higher overall (44/100 vs 21/100), backed by strong 163.3% margins and 14.0% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortress Biotech Inc Pref Series A
HEALTHCARE · BIOTECHNOLOGY · USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?